An integrative and comparative study of pan-cancer transcriptomes reveals distinct cancer common and specific signatures

To investigate the commonalities and specificities across tumor lineages, we perform a systematic pan-cancer transcriptomic study across 6744 specimens. We find six pan-cancer subnetwork signatures which relate to cell cycle, immune response, Sp1 regulation, collagen, muscle system and angiogenesis. Moreover, four pan-cancer subnetwork signatures demonstrate strong prognostic potential. We also characterize 16 cancer type-specific subnetwork signatures which show diverse implications to somatic mutations, somatic copy number aberrations, DNA methylation alterations and clinical outcomes. Furthermore, some of them are strongly correlated with histological or molecular subtypes, indicating their implications with tumor heterogeneity. In summary, we systematically explore the pan-cancer common and cancer type-specific gene subnetwork signatures across multiple cancers, and reveal distinct commonalities and specificities among cancers at transcriptomic level.

[1]  C. Wijmenga,et al.  Gene expression analysis identifies global gene dosage sensitivity in cancer , 2015, Nature Genetics.

[2]  K. Polyak,et al.  Intra-tumour heterogeneity: a looking glass for cancer? , 2012, Nature Reviews Cancer.

[3]  D. Pe’er,et al.  Integration of Genomic Data Enables Selective Discovery of Breast Cancer Drivers , 2014, Cell.

[4]  T. Fukushima,et al.  Roles of RAS and BRAF mutations in thyroid carcinogenesis. , 2005, Fukushima journal of medical science.

[5]  Joshua M. Stuart,et al.  The Cancer Genome Atlas Pan-Cancer analysis project , 2013, Nature Genetics.

[6]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[7]  Homin K. Lee,et al.  Coexpression analysis of human genes across many microarray data sets. , 2004, Genome research.

[8]  Hanlee P. Ji,et al.  Pan-cancer analysis of the extent and consequences of intratumor heterogeneity , 2015, Nature Medicine.

[9]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.

[10]  Josepa Ribes,et al.  Primary liver cancer: worldwide incidence and trends. , 2004, Gastroenterology.

[11]  P. Kaldis,et al.  Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms , 2009, Oncogene.

[12]  Gary D. Bader,et al.  GeneMANIA Cytoscape plugin: fast gene function predictions on the desktop , 2010, Bioinform..

[13]  David Warde-Farley,et al.  GeneMANIA: a real-time multiple association network integration algorithm for predicting gene function , 2008, Genome Biology.

[14]  Yan Li,et al.  Collagen as a double-edged sword in tumor progression , 2013, Tumor Biology.

[15]  Alexander E. Kel,et al.  TRANSFAC®: transcriptional regulation, from patterns to profiles , 2003, Nucleic Acids Res..

[16]  T. Zacharewski,et al.  pS2 (TFF1) levels in human breast cancer tumor samples: correlation with clinical and histological prognostic markers , 1999, Breast Cancer Research and Treatment.

[17]  Prahlad T. Ram,et al.  A pan-cancer proteomic perspective on The Cancer Genome Atlas , 2014, Nature Communications.

[18]  Benjamin J. Raphael,et al.  Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin , 2014, Cell.

[19]  Li Li,et al.  Gene co‐expression analysis identifies common modules related to prognosis and drug resistance in cancer cell lines , 2014, International journal of cancer.

[20]  Xia Li,et al.  Network-based survival-associated module biomarker and its crosstalk with cell death genes in ovarian cancer , 2015, Scientific Reports.

[21]  Chris Sander,et al.  Emerging landscape of oncogenic signatures across human cancers , 2013, Nature Genetics.

[22]  Nicolas Servant,et al.  A comprehensive evaluation of normalization methods for Illumina high-throughput RNA sequencing data analysis , 2013, Briefings Bioinform..

[23]  Mark D. Robinson,et al.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..

[24]  H. Moch,et al.  Chromosomal imbalances in papillary renal cell carcinoma: genetic differences between histological subtypes. , 1998, The American journal of pathology.

[25]  Shihua Zhang,et al.  Tumor characterization and stratification by integrated molecular profiles reveals essential pan-cancer features , 2015, BMC Genomics.

[26]  V. Trovisco,et al.  BRAF mutations are associated with some histological types of papillary thyroid carcinoma , 2004, The Journal of pathology.

[27]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[28]  Andrew E. Teschendorff,et al.  An integrative pan-cancer-wide analysis of epigenetic enzymes reveals universal patterns of epigenomic deregulation in cancer , 2015, Genome Biology.

[29]  C. Cordon-Cardo,et al.  Molecular pathways of urothelial development and bladder tumorigenesis. , 2010, Urologic oncology.

[30]  V. Weaver,et al.  The extracellular matrix modulates the hallmarks of cancer , 2014, EMBO reports.

[31]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  A. Giordano,et al.  Cell cycle kinases as therapeutic targets for cancer , 2009, Nature Reviews Drug Discovery.

[33]  M. Barbacid,et al.  Cell cycle, CDKs and cancer: a changing paradigm , 2009, Nature Reviews Cancer.

[34]  T. Lecuit,et al.  Molecular bases of cell-cell junctions stability and dynamics. , 2009, Cold Spring Harbor perspectives in biology.

[35]  Joshua M. Stuart,et al.  Subtype and pathway specific responses to anticancer compounds in breast cancer , 2011, Proceedings of the National Academy of Sciences.

[36]  Jorge S Reis-Filho,et al.  Triple-negative breast cancer. , 2010, The New England journal of medicine.

[37]  J. Azizkhan-Clifford,et al.  Sp1 and the ‘hallmarks of cancer’ , 2015, The FEBS journal.

[38]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[39]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[40]  Xiaofei Yang,et al.  Comparative pan-cancer DNA methylation analysis reveals cancer common and specific patterns , 2016, Briefings Bioinform..

[41]  G. Jay,et al.  HBx gene of hepatitis B virus induces liver cancer in transgenic mice , 1991, Nature.

[42]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[43]  Sandrine Dudoit,et al.  Evaluation of statistical methods for normalization and differential expression in mRNA-Seq experiments , 2010, BMC Bioinformatics.

[44]  Shihua Zhang,et al.  Toward a systematic understanding of cancers: a survey of the pan-cancer study , 2014, Front. Genet..

[45]  J. Lam,et al.  Novel approaches in the therapy of metastatic renal cell carcinoma , 2005, World Journal of Urology.

[46]  Yang Xiang,et al.  Weighted Frequent Gene Co-expression Network Mining to Identify Genes Involved in Genome Stability , 2012, PLoS Comput. Biol..

[47]  C. Müller-Tidow,et al.  Origins of aberrant DNA methylation in acute myeloid leukemia , 2014, Leukemia.

[48]  Shi-Hua Zhang,et al.  Identifying multi-layer gene regulatory modules from multi-dimensional genomic data , 2012, Bioinform..

[49]  Christian Ruckert,et al.  Influence of secreted frizzled receptor protein 1 (SFRP1) on neoadjuvant chemotherapy in triple negative breast cancer does not rely on WNT signaling , 2014, Molecular Cancer.

[50]  Sara J. Prest,et al.  The estrogen‐regulated protein, TFF1, stimulates migration of human breast cancer cells , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[51]  H. Oh,et al.  Low methylation levels of the SFRP1 gene are associated with the basal-like subtype of breast cancer. , 2013, Oncology reports.

[52]  Fabien Campagne,et al.  DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. , 2010, Cancer cell.

[53]  M. Robinson,et al.  A scaling normalization method for differential expression analysis of RNA-seq data , 2010, Genome Biology.

[54]  M. Newman,et al.  Finding community structure in networks using the eigenvectors of matrices. , 2006, Physical review. E, Statistical, nonlinear, and soft matter physics.

[55]  J. Reynolds,et al.  Cancer Cachexia: Mechanisms and Clinical Implications , 2011, Gastroenterology research and practice.

[56]  W. Rathmell,et al.  Renal cell carcinoma , 2007, Current opinion in oncology.

[57]  B. Reina-San-Martin,et al.  Deficiency in trefoil factor 1 (TFF1) increases tumorigenicity of human breast cancer cells and mammary tumor development in TFF1-knockout mice , 2011, Oncogene.

[58]  P. Gestraud,et al.  Independent component analysis uncovers the landscape of the bladder tumor transcriptome and reveals insights into luminal and basal subtypes. , 2014, Cell reports.

[59]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[60]  Russ B. Altman,et al.  Missing value estimation methods for DNA microarrays , 2001, Bioinform..

[61]  G. Kovacs,et al.  Molecular cytogenetics of renal cell tumors. , 1993, Advances in cancer research.

[62]  R. Tibshirani,et al.  Pancancer analysis of DNA methylation-driven genes using MethylMix , 2015, Genome Biology.

[63]  Jaak Vilo,et al.  g:Profiler—a web server for functional interpretation of gene lists (2011 update) , 2011, Nucleic Acids Res..

[64]  F. May,et al.  Interaction between TFF1, a gastric tumor suppressor trefoil protein, and TFIZ1, a brichos domain-containing protein with homology to SP-C. , 2005, Biochemistry.